These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35990619)

  • 1. Induced expression of CCL19 promotes the anti-tumor ability of CAR-T cells by increasing their infiltration ability.
    Hu JF; Wang ZW; Liao CY; Chen ZW; Kang FP; Lin CF; Lin TS; Huang L; Tian YF; Chen S
    Front Immunol; 2022; 13():958960. PubMed ID: 35990619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.
    Wehrli M; Guinn S; Birocchi F; Kuo A; Sun Y; Larson RC; Almazan AJ; Scarfò I; Bouffard AA; Bailey SR; Anekal PV; Montero Llopis P; Nieman LT; Song Y; Xu KH; Berger TR; Kann MC; Leick MB; Silva H; Salas-Benito D; Kienka T; Grauwet K; Armstrong TD; Zhang R; Zhu Q; Fu J; Schmidts A; Korell F; Jan M; Choi BD; Liss AS; Boland GM; Ting DT; Burkhart RA; Jenkins RW; Zheng L; Jaffee EM; Zimmerman JW; Maus MV
    Clin Cancer Res; 2024 May; 30(9):1859-1877. PubMed ID: 38393682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models.
    Goto S; Sakoda Y; Adachi K; Sekido Y; Yano S; Eto M; Tamada K
    Cancer Immunol Immunother; 2021 Sep; 70(9):2503-2515. PubMed ID: 33559069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton radiation boosts the efficacy of mesothelin-targeting chimeric antigen receptor T cell therapy in pancreatic cancer.
    Amit U; Uslu U; Verginadis II; Kim MM; Motlagh SAO; Diffenderfer ES; Assenmacher CA; Bicher S; Atoche SJ; Ben-Josef E; Young RM; June CH; Koumenis C
    Proc Natl Acad Sci U S A; 2024 Jul; 121(31):e2403002121. PubMed ID: 39047033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
    Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
    JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin.
    Pang N; Shi J; Qin L; Chen A; Tang Y; Yang H; Huang Y; Wu Q; Li X; He B; Li T; Liang B; Zhang J; Cao B; Liu M; Feng Y; Ye X; Chen X; Wang L; Tian Y; Li H; Li J; Hu H; He J; Hu Y; Zhi C; Tang Z; Gong Y; Xu F; Xu L; Fan W; Zhao M; Chen D; Lian H; Yang L; Li P; Zhang Z
    J Hematol Oncol; 2021 Jul; 14(1):118. PubMed ID: 34325726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model.
    Wang Y; Wang J; Yang X; Yang J; Lu P; Zhao L; Li B; Pan H; Jiang Z; Shen X; Liang Z; Liang Y; Zhu H
    Front Immunol; 2021; 12():628906. PubMed ID: 33777013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer.
    He J; Zhang Z; Lv S; Liu X; Cui L; Jiang D; Zhang Q; Li L; Qin W; Jin H; Qian Q
    Cell Immunol; 2018 Jul; 329():31-40. PubMed ID: 29859625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of AAV-CCL19 and GPC3 CAR-T Cells in the Treatment of Hepatocellular Carcinoma.
    Meng M; Wu YC
    J Immunol Res; 2021; 2021():1782728. PubMed ID: 34527749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.
    Hung CF; Xu X; Li L; Ma Y; Jin Q; Viley A; Allen C; Natarajan P; Shivakumar R; Peshwa MV; Emens LA
    Hum Gene Ther; 2018 May; 29(5):614-625. PubMed ID: 29334771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesothelin CAR-T cells secreting PD-L1 blocking scFv for pancreatic cancer treatment.
    Wang Y; Fang X; Li M; Ye J; Zhao S; Yu L; Wang J; Wang Y; Yan Z
    Cancer Genet; 2022 Nov; 268-269():103-110. PubMed ID: 36288641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Efficacy of IL7/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer.
    Ohta K; Sakoda Y; Adachi K; Shinozaki T; Nakajima M; Yasuda H; Nagano H; Tamada K
    Cancer Res Commun; 2024 Sep; 4(9):2514-2524. PubMed ID: 39240078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual targeting chimeric antigen receptor cells enhance antitumour activity by overcoming T cell exhaustion in pancreatic cancer.
    Ruixin S; Yifan L; Yansha S; Min Z; Yiwei D; Xiaoli H; Bizhi S; Hua J; Zonghai L
    Br J Pharmacol; 2024 Nov; 181(22):4628-4646. PubMed ID: 39129178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer.
    Ko AH; Jordan AC; Tooker E; Lacey SF; Chang RB; Li Y; Venook AP; Tempero M; Damon L; Fong L; O'Hara MH; Levine BL; Melenhorst JJ; Plesa G; June CH; Beatty GL
    Mol Ther; 2020 Nov; 28(11):2367-2378. PubMed ID: 32730744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma.
    Li T; Li H; Li S; Xu S; Zhang W; Gao H; Xu H; Wu C; Wang W; Yu X; Liu L
    Cancer Med; 2019 Sep; 8(11):5223-5231. PubMed ID: 31339230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models.
    Lee HH; Kim I; Kim UK; Choi SS; Kim TY; Lee D; Lee Y; Lee J; Jo J; Lee YT; Lee HJ; Kim SJ; Ahn JS
    Neoplasia; 2022 Feb; 24(2):98-108. PubMed ID: 34954452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma.
    Schomer NT; Jiang ZK; Lloyd MI; Klingemann H; Boissel L
    Cytotherapy; 2022 Aug; 24(8):827-834. PubMed ID: 35400595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors.
    Tomar S; Zhang J; Khanal M; Hong J; Venugopalan A; Jiang Q; Sengupta M; Miettinen M; Li N; Pastan I; Ho M; Hassan R
    Mol Cancer Ther; 2022 Jul; 21(7):1195-1206. PubMed ID: 35499461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineered T cells for pancreatic cancer treatment.
    Katari UL; Keirnan JM; Worth AC; Hodges SE; Leen AM; Fisher WE; Vera JF
    HPB (Oxford); 2011 Sep; 13(9):643-50. PubMed ID: 21843265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor.
    Moon EK; Carpenito C; Sun J; Wang LC; Kapoor V; Predina J; Powell DJ; Riley JL; June CH; Albelda SM
    Clin Cancer Res; 2011 Jul; 17(14):4719-30. PubMed ID: 21610146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.